Cancer R&D 2024 has wrapped up successfully. We’re grateful for your interest and interaction with Alfa Cytology. We’re eager to continue providing our expertise in cancer drug development. Let’s look back on these memorable moments!
Learn More
Invasive lobular carcinoma (ILC) is the most common "special" histological subtype of invasive breast cancer, accounting for up to 15% of all cases. At Alfa Cytology, our team of experienced biologists work with you to develop ILC therapeutics.
Invasive lobular carcinoma (ILC) is the second most common type of breast cancer diagnosed in the U.S., accounting for 10 to 15 percent of all invasive breast cancers diagnosed. ILC is notable for its distinct lack of E-cadherin function, which underlies the characteristic discohesive growth pattern observed, with individual tumor cells arranged in a single-file infiltrative manner and dispersed throughout the surrounding stroma. Typically, ILCs are of the luminal molecular subtype, expressing estrogen and progesterone receptors while lacking HER2 overexpression.
Fig.1 ILC subtypes by IHC. (McCart Reed, A.E., et al., 2021)
ILC is now recognized as a distinct disease process, and there is growing clinical evidence that a one-size-fits-all approach for all invasive breast cancers is not appropriate for specific subtypes such as ILC. As a result, a number of clinical trials have emerged to investigate ways to improve the therapeutic management of ILC.
| NCT | Category | Therapeutics | Phase |
| NCT02206984 | Endocrine Therapy | Tamoxifen + Anastrozole + Fulvestrant | |
| NCT02764541 | Cyclin-dependent Kinase Inhibitors + Endocrine Therapy | Letrozole + Tamoxifen + Palbociclib + Endocrine Therapy | |
| NCT03113825 | E-cadherin/ROS1 Inhibitor | Crizotinib + Fulvestrant | |
| NCT04551495 | Combination Therapy | Tyrosine Kinase Inhibitor + Letrozole + Goserelin |
At Alfa Cytology, we pride ourselves on our comprehensive suite of preclinical services tailored to the unique needs of ILC research. Our state-of-the-art facilities and highly trained personnel enable us to provide cutting-edge in vitro and in vivo models, as well as advanced imaging and molecular analyses, to support the development of innovative ILC therapies.
Therapeutics Development
Xenograft Model Development |
Genetic Engineering Model Development |
| Optional Cell Lines: SUM-44 PE, MDA-MB-134-VI, IPH-926, T69, T73, T78, LA-PDX1, BCM-3561, HCI-005, Others. | Optional Transgene: Trps1, Cdh1, Tp53, Pten, AKT, Myh9, t-ASPP2, Others. |
| Optional inoculation routes: systemic, local, orthotopic, subcutaneous, and intraductal injections. | Optional Species: Mouse, Rat, Dog, Zebrafish, Others. |
To learn more about our expertise in ILC research or to discuss potential collaborations, please don't hesitate to contact us at Alfa Cytology. We are committed to advancing the understanding and treatment of this important breast cancer subtype, and we welcome the opportunity to work with you in pursuit of this goal.
References
